Our top performer from yesterday’s report was most assuredly ABIO. We tagged this play after noticing that it had announced being granted orphan drug status by the FDA for “rNAPc2” as a potential treatment of viral hemorrhagic fever post-exposure to the Ebola virus.
Fresh FDA-related plays can often provide a healthy move to take advantage of, and that’s just what we got from ABIO, The stock traded in a range from .82-1.03, an intraday increase of 25% on nearly ten times the 3-month average volume.
Our long-time readers might recall our coverage of this stock last year in December, which sort of got lost in the shuffle that was the hysteria created by the “Green Rush”. We tracked the stock from the low 1.40’s to over 2.20 over a period of a few weeks, so it will be interesting to see if history continues to repeat itself with ABIO, especially with the stock coming off of it 52-week low on Tuesday.
CYREN Ltd. CYRN
We also wanted to acknowledge the early morning move made by another of the stocks we mentioned in yesterday’s newsletter, CYRN. It bolted out of the gate, quickly running from 2.22 to 2.67, a 20% spike within the first 15 minutes of the session.
The stock got hammered into the close quite a bit, so we’ll be open to the possibility of seeing some bounce action, provided it can hold support at or above the 50DMA of 1.75.
Office Depot, Inc. ODP
ODP is in the midst of making a big move on the heels of large activist investor Starboard Value taking up a position which equates to 6% of ODP’s total shares. It also upped its stake in Staples to 10% fueling speculation that it could create pressure for the two office supply giants to merge. It will definitely be a story that we’ll be interested to follow moving forward.
Extended Watchlist:
GPT, RGDX, CYTX, DRD